Cardiff Oncology (CRDF) Competitors

$1.73 +0.04 (+2.37%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$1.72 0.00 (-0.29%)

As of 04:13 AM Eastern

CRDF vs. ADCT, ENTA, AGMB, AVIR, and CABA

Should you buy Cardiff Oncology stock or one of its competitors? MarketBeat compares Cardiff Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiff Oncology include ADC Therapeutics (ADCT), Enanta Pharmaceuticals (ENTA), AgomAb Therapeutics (AGMB), Atea Pharmaceuticals (AVIR), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.

How does Cardiff Oncology compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

ADC Therapeutics presently has a consensus price target of $8.00, indicating a potential upside of 137.04%. Cardiff Oncology has a consensus price target of $10.10, indicating a potential upside of 483.82%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Cardiff Oncology had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for Cardiff Oncology and 1 mentions for ADC Therapeutics. Cardiff Oncology's average media sentiment score of -0.37 beat ADC Therapeutics' score of -0.49 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADC Therapeutics has a beta of 1.83, meaning that its stock price is 83% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cardiff Oncology has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$79.18M	5.42	-$142.62M	-$1.05	N/A
Cardiff Oncology	$590K	200.47	-$45.85M	-$0.69	N/A

ADC Therapeutics has a net margin of -173.02% compared to Cardiff Oncology's net margin of -7,733.22%. ADC Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%

Summary

Cardiff Oncology beats ADC Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Cardiff Oncology has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.14	-$81.89M	-$2.59	N/A
Cardiff Oncology	$590K	200.47	-$45.85M	-$0.69	N/A

Enanta Pharmaceuticals has a net margin of -89.56% compared to Cardiff Oncology's net margin of -7,733.22%. Enanta Pharmaceuticals' return on equity of -68.72% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-68.72%	-20.41%
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 7.7% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Enanta Pharmaceuticals had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 6 mentions for Enanta Pharmaceuticals and 3 mentions for Cardiff Oncology. Enanta Pharmaceuticals' average media sentiment score of -0.01 beat Cardiff Oncology's score of -0.37 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Cardiff Oncology	Neutral

Enanta Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Enanta Pharmaceuticals presently has a consensus target price of $20.29, indicating a potential upside of 46.89%. Cardiff Oncology has a consensus target price of $10.10, indicating a potential upside of 483.82%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Enanta Pharmaceuticals beats Cardiff Oncology on 10 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

AgomAb Therapeutics has higher earnings, but lower revenue than Cardiff Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Cardiff Oncology	$590K	200.47	-$45.85M	-$0.69	N/A

AgomAb Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,733.22%. AgomAb Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%

16.3% of Cardiff Oncology shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for AgomAb Therapeutics and 3 mentions for Cardiff Oncology. AgomAb Therapeutics' average media sentiment score of 0.30 beat Cardiff Oncology's score of -0.37 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AgomAb Therapeutics presently has a consensus target price of $32.00, indicating a potential upside of 189.86%. Cardiff Oncology has a consensus target price of $10.10, indicating a potential upside of 483.82%. Given Cardiff Oncology's higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

AgomAb Therapeutics beats Cardiff Oncology on 6 of the 11 factors compared between the two stocks.

How does Cardiff Oncology compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Cardiff Oncology has a consensus target price of $10.10, indicating a potential upside of 483.82%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Cardiff Oncology has higher revenue and earnings than Atea Pharmaceuticals. Cardiff Oncology is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Cardiff Oncology	$590K	200.47	-$45.85M	-$0.69	N/A

Atea Pharmaceuticals has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,733.22%. Atea Pharmaceuticals' return on equity of -57.01% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%

Atea Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 18.1% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Atea Pharmaceuticals had 5 more articles in the media than Cardiff Oncology. MarketBeat recorded 8 mentions for Atea Pharmaceuticals and 3 mentions for Cardiff Oncology. Atea Pharmaceuticals' average media sentiment score of 0.90 beat Cardiff Oncology's score of -0.37 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Atea Pharmaceuticals beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Cabaletta Bio?

Cardiff Oncology (NASDAQ:CRDF) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Cabaletta Bio has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,733.22%. Cardiff Oncology's return on equity of -82.01% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%
Cabaletta Bio	N/A	-121.73%	-90.19%

In the previous week, Cabaletta Bio had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 5 mentions for Cabaletta Bio and 3 mentions for Cardiff Oncology. Cabaletta Bio's average media sentiment score of 1.04 beat Cardiff Oncology's score of -0.37 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cabaletta Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiff Oncology has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.18, indicating that its share price is 218% more volatile than the broader market.

Cardiff Oncology has higher revenue and earnings than Cabaletta Bio. Cardiff Oncology is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	200.47	-$45.85M	-$0.69	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$2.28	N/A

16.3% of Cardiff Oncology shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cardiff Oncology presently has a consensus target price of $10.10, indicating a potential upside of 483.82%. Cabaletta Bio has a consensus target price of $17.00, indicating a potential upside of 370.91%. Given Cardiff Oncology's higher possible upside, equities research analysts plainly believe Cardiff Oncology is more favorable than Cabaletta Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cabaletta Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Cardiff Oncology beats Cabaletta Bio on 8 of the 15 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDF vs. The Competition

Export

Metric	Cardiff Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$115.54M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-2.51	18.47	20.66	25.63
Price / Sales	200.47	294.84	547.02	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	2.58	6.93	9.93	6.97
Net Income	-$45.85M	$24.11M	$3.55B	$333.62M
7 Day Performance	5.49%	5.89%	1.69%	1.09%
1 Month Performance	1.76%	-0.91%	0.48%	3.08%
1 Year Performance	-37.09%	74.58%	39.38%	35.68%

Cardiff Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDF Cardiff Oncology	1.7226 of 5 stars	$1.73 +2.4%	$10.10 +483.8%	-35.2%	$115.54M	$590K	N/A	20	Earnings Report
ADCT ADC Therapeutics	2.1468 of 5 stars	$3.50 -0.1%	$8.00 +128.9%	+88.0%	$445.17M	$81.36M	N/A	310
ENTA Enanta Pharmaceuticals	2.0568 of 5 stars	$15.46 +0.8%	$20.29 +31.2%	+166.6%	$445.16M	$65.32M	N/A	160	Earnings Report Analyst Revision High Trading Volume
AGMB AgomAb Therapeutics	N/A	$12.18 +0.4%	$32.00 +162.7%	N/A	$441.37M	N/A	N/A	62	News Coverage Short Interest Increase
AVIR Atea Pharmaceuticals	1.107 of 5 stars	$5.41 -0.4%	N/A	+67.5%	$434.55M	N/A	N/A	70	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDF) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiff Oncology (CRDF) Competitors

CRDF vs. ADCT, ENTA, AGMB, AVIR, and CABA

How does Cardiff Oncology compare to ADC Therapeutics?

Summary

How does Cardiff Oncology compare to Enanta Pharmaceuticals?

Summary

How does Cardiff Oncology compare to AgomAb Therapeutics?

Summary

How does Cardiff Oncology compare to Atea Pharmaceuticals?

Summary

How does Cardiff Oncology compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiff Oncology (CRDF) Competitors

CRDF vs. ADCT, ENTA, AGMB, AVIR, and CABA

How does Cardiff Oncology compare to ADC Therapeutics?

Do analysts prefer ADCT or CRDF?

Does the media refer more to ADCT or CRDF?

Which has more volatility and risk, ADCT or CRDF?

Do insiders & institutionals believe in ADCT or CRDF?

Which has better valuation and earnings, ADCT or CRDF?

Is ADCT or CRDF more profitable?

Summary

How does Cardiff Oncology compare to Enanta Pharmaceuticals?

Which has preferable earnings and valuation, ENTA or CRDF?

Is ENTA or CRDF more profitable?

Do institutionals & insiders believe in ENTA or CRDF?

Does the media refer more to ENTA or CRDF?

Which has more volatility & risk, ENTA or CRDF?

Do analysts rate ENTA or CRDF?

Summary

How does Cardiff Oncology compare to AgomAb Therapeutics?

Which has better earnings & valuation, AGMB or CRDF?

Is AGMB or CRDF more profitable?

Do insiders and institutionals believe in AGMB or CRDF?

Does the media favor AGMB or CRDF?

Do analysts rate AGMB or CRDF?

Summary

How does Cardiff Oncology compare to Atea Pharmaceuticals?

Do analysts rate AVIR or CRDF?

Which has better earnings & valuation, AVIR or CRDF?

Is AVIR or CRDF more profitable?

Which has more risk & volatility, AVIR or CRDF?

Do insiders and institutionals believe in AVIR or CRDF?

Does the media prefer AVIR or CRDF?

Summary

How does Cardiff Oncology compare to Cabaletta Bio?

Is CRDF or CABA more profitable?

Does the media prefer CRDF or CABA?

Which has more volatility and risk, CRDF or CABA?

Which has preferable earnings and valuation, CRDF or CABA?

Do institutionals and insiders believe in CRDF or CABA?

Do analysts rate CRDF or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools